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The field of stem cell research has grown to include a vibrant international community of scientists and clini-
cianswho come fromboth academia and industry andwho strive to shed light on the biology of these remark-
able cells and find applications in drug discovery, disease modeling, and regenerative medicine.Introduction
The study of stem cell biology as a scien-
tific discipline distinct from its roots in he-
matology, cancer biology, immunology,
developmental biology, and neuroscience
traces back to landmark findings in the
late 1990s. Such findings include the
cloning of Dolly the sheep (Campbell
et al., 1996) and the first successful deri-
vation of human embryonic stem (ES)
cells (Thomson et al., 1998). In a remark-
ably short time-span, the field has at-
tracted an extraordinary level of public
expectation and government support for
its potential applications in regenerative
medicine, but it has also attracted signifi-
cant political and ethical controversy over
the use and manipulation of human bio-
logic materials in some studies. Research
and policy approaches to stem cell bio-
logy have coevolved, and the field has
become a truly global enterprise.
One striking aspect of the international
stem cell research community is the di-
versity and depth it has achieved in a short
span. A number of smaller nations, such
as Israel, Sweden, and Singapore, have
punched well above their weight by iden-
tifying and concentrating their efforts in
specific niches within the field, whereas
many other countries with comparatively
scant prior experience in advanced bio-
medical research and development, no-
tably China and Korea, have built compet-
itive research facilities and programs from
the ground up. Meanwhile, religious and
political debates over issues such as the
use of human embryos for research,
somatic cell nuclear transfer (‘‘therapeutic
cloning’’), and the generation of human-
animal hybrids have created problems
for, and in some cases prevented, work
in this field in major research nations,including the United States, Germany,
and Australia. Indeed, the funding res-
trictions on human ES cell research in
the USA might have inspired countries,
many of them in Asia, that had not histor-
ically conducted leading biomedical re-
search to promote such research through
specific regulatory and funding initiatives.
Despite the limitations imposed on fed-
eral funding, however, the United States
has showed great robustness and inge-
nuity in developing alternative funding
sources for stem cell research, for ex-
ample through industry and philanthropic
investment, patient activism, and funding
initiatives by individual states. This de-
federalization of stem cell research fund-
ing is exemplified by the California
Institute of Regenerative Medicine, which
has led a $3 billion commitment over 10
years (CIRM, 2011). Other factors,
including the country’s powerful research
universities, a tradition of scientific entre-
preneurialism, regulatory clarity, and the
sheer size of its life sciences and biotech-
nology communities have ensured that
even in the face of numerous nonscientific
hurdles and intense international compe-
tition, the United States remains the
leader in most important metrics of
productivity, including publications,
patents, and funding.
European Unity
This is not, however, to minimize the
contributions of other regions of the
world. In Europe, multiple countries have
shown consistently strong support for
and high levels of achievement in stem
cell research. The United Kingdom was
instrumental in leading efforts to develop
transparent, reasoned policies over the
use of human embryos for research,Neuronnuclear transfer, and the creation of
human ‘‘admixed’’ embryos. With strong
concentrations of talent and facilities
in London, Cambridge, and Edinburgh,
among others, UK stem cell biologists
have made advances in fundamental
biology and are leading the development
of stem-cell-based treatments for stroke
and macular degeneration. Sweden has
developed dozens of human ES cell lines
and has conducted pioneering clinical
studies of fetal cell transplantation in the
treatment of Parkinson disease; these
studies have helped to spur interest in
the use of stem cells in treating neuro-
degenerative disorders. Germany, ham-
pered by longstanding legal barriers to
human ES cell research, has established
centers of excellence for the study of
somatic stem cells and their potential
use in regenerative medicine in Berlin,
Munich, and the North Rhine/Westphalia
region. In Barcelona, a joint investment
by the Spanish national and Catalonian
state governments has created a research
park that is home to institutes such as the
Center for Genomic Regulation and the
Center for Regenerative Medicine with
superior faculties and facilities support.
Intraregional cooperation and outreach
has also been a successful feature of
stem cell science within the EU. In one
famous example, a collaboration between
scientists andclinicians inSpain, Italy, and
the UK achieved a breakthrough proof-of-
concept demonstration of the decellulari-
zation-recellularization approach to tissue
replacement in 2009 when they used
a patient’s own stem cells to repopulate
a transplantable allogeneic tracheal seg-
ment that had been denuded of the
donor’s cells (Macchiarini et al., 2008). The
European Science Foundation launched70, May 26, 2011 ª2011 Elsevier Inc. 573
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research and comparative analyses of
stem cells from various sources, and the
FP6 program supported the development
of a much-needed online database of
human embryonic stem cell lines, known
as hESCreg (hESCreg, 2009). The Euro-
StemCell project established under the
FP7 program in 2010 brings together
scientists and communicators from
around 90 stem cell laboratories to en-
gage with the public about their work
(EuroStemCells, 2011).
The unifying structure of the EU has not,
however, entirely eliminated policy differ-
ences between countries, and it has failed
to bridge the considerable gap between
member states in areas such as human
ES cell research regulations. Recently,
EU stem cell scientists have expressed
growing concern over the possibility that
patents based on human ES cell technol-
ogies will be disallowed on the grounds
that they would offend public morality.
A coalition of prominent scientists have
argued that such a decision would do
irreparable harm to the ability of EU scien-
tists and companies to compete in this
area.
Asia Comes of Age
The governments of many nations in Asia
and Oceania have shown extraordinary
support for the development of stem cell
research and application within their
borders. China, Korea, Singapore, India,
and Taiwan have all invested unprece-
dented amounts in stem cell research
since 2001, and Japan and Australia
have built on their historical strengths in
basic biology and clinical development
to create leading stem cell institutes
in Kyoto, Kobe, and Melbourne (Sipp,
2009). Progress has not always been
smooth—the scandal surrounding Woo-
Suk Hwang’s fraudulent claims of somatic
cell nuclear transfer highlighted weak-
nesses in the funding and oversight
systems that Korea, to its credit, was
quick to rectify—and, with the exception
of Japan and more recently China,
productivity has been incommensurate
with funding levels.
The Asia-Pacific region lacks a govern-
ing organization equivalent to that of the
EU, and this defecit continues to make
the establishment of region-wide stem
cell research programs and collabora-574 Neuron 70, May 26, 2011 ª2011 Elseviertions difficult. In 2007, Stem Cell Network:
Asia-Pacific (SNAP) was launched by
scientists from eight countries in the
region, but the organization has failed to
attract sustained funding or activity levels
in recent years. At the national level, many
Asian countries have organized strong
national stem cell societies; some, such
as those in Singapore, Taiwan, and Korea,
have hundreds of members representing
dozens of labs. Japan lacks a stem cell
society per se, but the Japanese Society
for Regenerative Medicine has well over
2,000 members. Unfortunately, the lack
of a regional entity to coordinate stem
cell research and development has led in
some cases to redundancy and needless
competition in the building of stem cell
banks and the scheduling of international
symposia.
Although regulations of the use of
human embryos for research have tended
to be quite favorable inmuch of the region,
several countries have been caught off
guard by a lack of preparedness for the
clinical translation of stem cell research,
and numerous clinics advertising spurious
stem cell injections for the treatment of
a wide range of medical conditions have
put patients in harm’s way and damaged
the reputations of legitimate scientists
working in the same country. Efforts
have been made to address such unregu-
lated uses of stem cells and have resulted
in new regulations in Thailand and China,
and the national prosecutor’s office in Ko-
rea investigated one company that had
been recruiting patients to receive stem
cell injections overseas.
Stem Cells on the Global Stage
A number of organizations bring together
scientists and stakeholders from around
the world to promote the field. Preeminent
among these is the International Society
for Stem Cell Research (ISSCR), with
more than 3600 members from more
than 40 countries representing academia,
industry, government, and philanthropic
organizations (ISSCR, 2011). The ISSCR
works to promote global discussion on
the latest advances in stem cell research
in its annual meetings, which are held on
a rotating basis in North America, Europe,
and the Asia-Oceania region, as well as to
conduct educational and public-engage-
ment activities around the world. It has
producedconsensusguidelinesonhumanInc.ES cell research and the clinical transla-
tion of stem cell technologies, as well as
information for patients considering stem
cell treatments.
Other, more clinically oriented interna-
tional groups focusing on stem cells and
regenerativemedicine include the Interna-
tional Society of Cellular Therapy (ISCT)
and TERMIS, both of which gather re-
searchers and clinicians from academia
and industry to discuss the development
of human cell- and tissue-based medical
products and procedures. Support for
international research efforts, with a par-
ticular focus on human ES cell character-
ization, banking, and cultural standards,
has been provided for nearly ten years
by the International Stem Cell Forum,
which comprises nearly 20 national and
other funding agencies. The Interna-
tional Consortium of Stem Cell Networks
brings together support and promotion
organizations from many countries, most
notably Canada, Australia, and Germany.
Industry meetings, research institutes,
and national societies all also regularly
hold international conferences and work-
shops on the full spectrum of stem cell
research, ensuring that scientists in the
field are confronted by an embarrassment
of choices when making their conference
schedules.
New Discoveries, New Directions
Much of the first half of the first decade of
the 21st century saw the field dominated
by controversy and uncertainty over ques-
tions such as the moral status of human
blastocysts, the comparative advantages
of ES and somatic stem cells, and the
rush todevelop stemcell-based transplan-
tation procedures for use in regenerative
medicine. Thefirst report of inducedplurip-
otent stem (iPS) cells in 2006 (Takahashi
andYamanaka, 2006) had a transformative
effect on the fieldbecause it paved theway
to an alternative source for human pluripo-
tent stem cells; this new source was much
less encumbered than human ES cell
research by ethical concerns. Although
the initial discovery was made by a Japa-
nese laboratory, it paradoxically strength-
ened the hand of US-based researchers
who were freed from the funding restric-
tions and legal and political disputes that
had dogged human ES cell research, and
at present it is the US rather than Japan
that dominate iPS cell research. The
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vested heavily in the field and has
created a Center for iPS Cell Research
and Application led by Shinya Yamanaka
at Kyoto University; China has also
ramped up its stem cell investment,
including its investment in many iPS cell
labs, in its most recent national 5 yr
spending plan.
Technological developments have also
led to a number of industry-funded clinical
trials of stem cell-based treatments for
conditions such as heart failure, spinal
cord injury, cerebrovascular accident,
and amyotrophic lateral sclerosis. In all
cases, however, these studies are at the
earliest stages of safety testing, and the
road to regulatory approval will doubtless
be long and fraught with challenges. After
the excitement of the first days of inten-
sive stem cell research, the reality of the
unique challenges of cell-based products
has set in. Scientists, physicians, and
regulators alike have recognized the risks
and limitations imposed by the ability of
stem cells of various types to proliferate,
differentiate, home to wound and tumor
sites, and secrete multiple molecular
factors; indeed, nearly every property of
potential clinical benefit also represents
a potential risk. Whether stem cells or
their derivatives will be able to integrate
into target tissues, particularly dynamic
or complex environments such as cardiac
muscle or the nervous system, and lead to
the restoration of physiological function
remains very much an open question,
and concerns have also been raised that
some degenerative diseases might be
associated with pathogenic tissue envi-
ronments capable of damaging or trans-
forming stem cells, which might further
complicate their use in the treatment of
such conditions. Furthermore, the long-
term genetic and karyotypic stability of
stem cells in vivo outside the hematopoi-
etic system is largely unknown, and any
treatment protocol that calls for cells to
functionally integrate and survive for the
life of the patient will need to include
provisions for follow-up and surveillance
over the long term. It will be important
for scientists, policymakers, and funding
bodies to remain focused and alert for
opportunities in the development of true
stem cell-based treatments while main-
taining realistic and responsible oversight
to ensure patient safety and public trust.At the same time, a number of potential
stem cell applications that do not follow
the ‘‘cell therapy’’ paradigm have gained
prominence in recent years. The advent
of human iPS cells has opened up pos-
sibilities for the generation of large, pure
populations of differentiated cells, such
as cardiomyocytes, hepatocytes, and
neurons of various types, which could
prove invaluable as test beds for use in
drug discovery, toxicology testing, and
disease modeling. These have the added
advantage of serving as a potential re-
placement for some types of animal
studies, provided that human cells in vitro
can be shown to differentiate into phys-
iological tissue and mimic disease states
with sufficient accuracy. Stem Cells for
SaferMedicine (SC4SM, 2010), a coalition
that includes threemajor drug companies,
has already been formed with the aim of
exploring the possibilities of stem cells in
pharmaceutical development.
Results from some clinical studies using
mesenchymal stem cells (MSCs) have
shown transient benefits but poor cell
survival, leading to speculation that the
effectsmight be due to paracrine secretion
of cytokines and other factors, whichmight
trigger wound healing or angiogenesis or
modulate the immune response. Bio-pro-
specting research into such stem cells
might reveal the specific cocktails of
factors able to elicit such healing res-
ponses, and if isolated and tested, such
factors might one day lead to the develop-
ment of ‘‘cell therapy without cells.’’ Simi-
larly, there have been proposals to use
MSCs, which have been shown to home
to sites of tissue damage and tumorigen-
esis, asvehicles for thedeliveryofbioactive
molecules or nanomaterials. Finally, the
discovery that cell fates can be reprog-
rammed, as evidenced by the transforma-
tionoffibroblasts intopluripotentstemcells
in the iPS cell process, might lead to
new advances in direct reprogramming
between differentiated cells types; such
reprogramming has already been demon-
strated in the conversion of exocrine into
endocrine cells in the pancreas (Zhou
et al., 2008) and in the conversion of B cells
into macrophages in the blood system
(Bussmann et al., 2009). Although these
alternative uses of stem cells might have
less charismatic appeal than the classic
concept of cell transplantation, they could
allow important successes in the nearNeuronterm while studies on more challenging
clinical applications move forward.
The unregulated use of stem cells in
medicine, often referred to as ‘‘stem cell
tourism,’’ remains one of the greatest
threats to patients and to the field itself
(Taylor et al., 2010). Hundreds of compa-
nies market untested stem cell products
and injections for an extremely broad
range of diseases, many of which, such
as spinal cord injury, ALS, autism, Parkin-
son disease, and multiple sclerosis, affect
the nervous system. Strides have been
made in reining in such unscrupulous
behavior after multiple incidents of tumor-
igenesis and death as the result of compli-
cations following injections of cells into
the brainstem or carotid artery, but com-
panies have shown great resourcefulness
in their ability to evade oversight and lure
patients. The international stem cell com-
munity has been extremely active in
combatting the premature commerciali-
zation of stem cell treatments and will
need to continue to work with authorities,
patient groups, and media organizations
to inform and protect patients from such
practices.
Stem cell research continues to be one
of themost exciting and highly anticipated
fields of biological research, and it enjoys
exceptional support from funding agen-
cies and the general public in countries
around the world. The road to applica-
tions will be a long one, and numerous
hurdles lie ahead. The success of the field
will continue to rely heavily on funda-
mental research to provide a solid basis
of understanding for clinical studies, and
scientists in all countries will need to
continue to collaborate, share, compete,
and strive together if the extraordinary
promise of stem cell research is to be
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